FDA proposes withdrawing TAVNEOS approval after trial-data and liver-injury findings
The FDA proposed withdrawing U.S. approval of TAVNEOS, a treatment for adults with severe ANCA-associated vasculitis, after identifying manipulated pivotal-trial results, undisclosed analyses and serious liver injuries.